ERBB2 and breast carcinoma: In the KRISTINE study, the tpCR rate of 18‐week neoadjuvant chemotherapy combined with dual HER2‐targeted agents in patients with HR‐negative, HER2‐positive breast cancer was 73.2%, but that in patients with HR‐positive, HER2‐positive breast cancer was only 43.8%.13